Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Somatostatin Receptor Scintigraphy in Pituitary Adenomas: A Somatostatin Receptor Density Index Can Predict Hormonal and Tumoral Efficacy of Octreotide In Vivo

Michèle Duet, Christiane Ajzenberg, Salah Benelhadj, Elisabeth Lajeunie, Boris Lormeau, Pierre-Jean Guillausseau, Vincens Rohmer, Didier Vilain, Olivier Mundler and André Warnet
Journal of Nuclear Medicine August 1999, 40 (8) 1252-1256;
Michèle Duet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Ajzenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salah Benelhadj
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabeth Lajeunie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boris Lormeau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre-Jean Guillausseau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincens Rohmer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Didier Vilain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Mundler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
André Warnet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 40, Issue 8
August 1, 1999
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Advertising (PDF)
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Somatostatin Receptor Scintigraphy in Pituitary Adenomas: A Somatostatin Receptor Density Index Can Predict Hormonal and Tumoral Efficacy of Octreotide In Vivo
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Somatostatin Receptor Scintigraphy in Pituitary Adenomas: A Somatostatin Receptor Density Index Can Predict Hormonal and Tumoral Efficacy of Octreotide In Vivo
Michèle Duet, Christiane Ajzenberg, Salah Benelhadj, Elisabeth Lajeunie, Boris Lormeau, Pierre-Jean Guillausseau, Vincens Rohmer, Didier Vilain, Olivier Mundler, André Warnet
Journal of Nuclear Medicine Aug 1999, 40 (8) 1252-1256;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Somatostatin Receptor Scintigraphy in Pituitary Adenomas: A Somatostatin Receptor Density Index Can Predict Hormonal and Tumoral Efficacy of Octreotide In Vivo
Michèle Duet, Christiane Ajzenberg, Salah Benelhadj, Elisabeth Lajeunie, Boris Lormeau, Pierre-Jean Guillausseau, Vincens Rohmer, Didier Vilain, Olivier Mundler, André Warnet
Journal of Nuclear Medicine Aug 1999, 40 (8) 1252-1256;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size
  • Google Scholar

More in this TOC Section

  • First-in-Human Study of 18F-Labeled PET Tracer for Glutamate AMPA Receptor [18F]K-40: A Derivative of [11C]K-2
  • Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis
  • [11C]Carfentanil PET Whole-Body Imaging of μ-Opioid Receptors: A First in-Human Study
Show more Clinical Investigation

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire